الفهرس | Only 14 pages are availabe for public view |
Abstract Summary Postoperative pain of laparoscopic cholecystectomy (LC) is less intense than that of open cholecystectomy, and LC is typically performed as ambulatory surgery, although the approach is not pain-free. Especially, some patients complain of severe pain during the first 24 hours after LC. The origin of pain after LC is complicated. Thus, a combination of inflammatory, incisional somatic, and visceral components, multimodal analgesic regimens and various treatments are suggested, which include opioids, NSAIDs, dexamethasone, injection of local anesthetics into the surgical wound, and removal of residual carbon dioxide. Intravenous lidocaine has analgesic, anti-hyperalgesic, and antiinflammatory effects due to sodium channel blockade and inhibition of Nmethyl- D-aspartate (NMDA) receptors. Intravenous lidocaine provides pain relief after open abdominal and laparoscopic surgeries including LC. Dexmedetomidine is a specific α2-adrenergic receptor agonist that has anti-nociceptive and sedative properties. Intravenous dexmedetomidine has a role as postoperative analgesia, which leads to the reduced requirement for opioids. The aim of this study is to evaluate the effect of intravenous infusion of Lidocaine versus Dexmedetomidine on consumption of analgesics during laparoscopic cholecystectomy. This triple blind randomized controlled study was carried out on 60 patients aged 20 – 60 years old, both sex, ASA physical status I or II scheduled for elective laparoscopic cholecystectomy under general anesthesia. |